Health Check: For ASX biotechs, the business of America remains business
Imagion shares almost double on positive FDA feedback
Quiet drug developer PYC Therapeutics wins a friend
The US healthcare system is mired down by kerfuffles over tariffs, drug pricing and cuts to regulatory and funding bodies, but for ASX biotechs the wheels of decision-making keep grinding.
As President Calvin Coolidge (supposedly) said a century ago, 'the business of America is business' and that will never be Trumped.
Among a slew of US-related disclosures, Orthocell (ASX:OCC) notes it has pocketed its first US revenue from its flagship nerve repair device, Remplir.
The achievement follows Remplir's first surgical use in the US, for a foot repair in Ohio on June 26.
The company also cites revenue from 'subsequent early surgical cases in Florida, sourced from the company's network of specialist distributors'.
Orthocell's commercial traction comes just three months after the company won US Food and Drug Administration clearance for Remplir, which wraps around peripheral nerves and protects them during surgery.
Yesterday Orthocell reported June quarter revenue of $2.73 million, up 22.8% on the record March quarter.
This took annual revenue to $9.19 million, up 35.8%.
Crucially, that does not include Remplir US revenue.
First US revenue for Artrya, too
Meanwhile, heart device maker Artrya (ASX:AYA) has announced its first US revenue for its Salix coronary plaque detection platform.
This is by way of a US$600,000, five-year contract with the Georgia and Alabama based Tanner Health.
Tanner has a network of five hospitals, cardiovascular centres, and 30 physician practices.
'This first revenue represents a major milestone for Artrya as it continues to transition to a revenue-stage business,' the company says.
The FDA approved Artrya's device in March.
So like Orthocell, it's not wasting any time in monetising the opportunity.
Artrya is 'actively progressing' commercial discussions with other US hospital networks.
The company is also girding for FDA clearance of a further module.
US approval? Imagion that
Imagion Biosystems (ASX:IBX) today almost doubled after the company said it had received positive FDA feedback on the company's proposed phase II imaging trial for HER-2 positive breast cancer.
The company aims to detect cancers early with its Magsense imaging tech.
Magsense combines the use of magnetically detectable nanoparticles with biological agents.
The underlying tech, by the way, was created by a Los Alamos, New Mexico physicist called Edward R Flynn. The good doc tinkered with magnetic sensors after his wife contracted breast cancer.
The company plans to lodge an Investigative New Drug Application – that is, assent to start a trial – with the FDA in the current quarter.
Imagion says the agency provided 'positive feedback and constructive input regarding the study plan and outcomes.'
'I'm very pleased with the trajectory of our communications with the FDA', says Imagion exec chairman Bob Proulx.
Investors were pleased as well: the FDA's kind words sent the stock up as much as 92% this morning.
Imricor wins Northstar approval
Coming back to heart health, Imricor Medical Systems (ASX:IMR) has won European regulatory approval for Northstar, as well as its second-generation ablation catheters and capital equipment.
This was under the Continent's European Medical Device Regulation, a more stringent gateway than the old rules.
Imricor has developed the world's only MRI-guided ablation catheter, which are single-use consumables.
Consisting of a workstation and software, Northstar is key to making the magic happen.
In mid-April the European gatekeepers approved the catheters under the old pathway.
'Investments in sales and marketing are beginning to pay dividends, with the number of hospitals in the active European pipeline increasing from seven to 26 over the past six months,' Imricor says.
As always, the US presents the biggest market. There, the company has lodged vital documentation with the FDA as part of the Northstar approval process.
The company aims to submit all its supportive clinical data by the first half of 2026.
'Approval of Northstar will mark the commercial entry point for Imricor in the US and enable Imricor's sales team to initiate site engagement and pipeline development,' the company says.
Mach 7 maintains cruising altitude
ProMedicus (ASX:PME) 'mini me' Mach7 Technologies (ASX:M7T) has affirmed its revenue forecast for the year to June 2025, albeit at the lower end of things.
Mach 7 also expects to break even.
On preliminary unaudited numbers, Mach 7 expects revenue of $33-34 million, in line with guidance of $33-36 million and 15-25% higher than previously.
Management expects recurring revenue – subscription revenue and maintenance and support revenue – to be 20% higher.
But CARR – contracted annual recurring revenue - should come in at $30-31 million, just below the guided $32-35 million.
'Mach 7 is in a strong financial position with no debt and expects to be operating cash flow positive for the 2024-25 year,' management chirps.
Mach 7 provides medical imaging software, including image diagnosis and vendor-neutral image archiving.
In crude terms Mach7 is 'same but different' to Pro Medicus – a key commonality being a US focus.
But they don't compete directly, by and large.
A key difference, of course, is that Mach 7 is worth $80 million, with $22 million of cash backing.
Pro Medicus is valued at $33 billion, with its shares surging 140% over the last year.
Mach 7 shares have decline 44% over his period.
Sniffing a bargain, Mach 7 is lapping up its own shares by way of an ongoing share buyback.
Mach 7's new CEO Teri Thomas officially started on July 1 and will update investors on July 29.
Thomas headed breast imaging outfit Volpara Technologies, before it was taken over by a South Korean suitor last year.
Why we like PYC
Drug developer PYC Therapeutics (ASX:PYC) has maintained a low profile and that's partly because of its convoluted story over the years.
But the Perth-based PYC now has a clearer focus on a portfolio of four rare disease candidates for rare inherited diseases, across three clinical trials.
Growing investor awareness has pushed PYC's market cap to more than $840 million.
Broker Bell Potter reckons there's room for more as PYC 'has continued to execute impressively in recent months.'
PYC's trials cover the eye diseases retinitis pigmentosa type 11 (RP11) and autosomal dominant optic atrophy (ADOA), as well as polycystic kidney disease (PKD).
The most advanced, RP11 is fully recruited should start a registrational phase 2/3 trial in the next six to nine months. This follows recent FDA feedback on trial design.
'Early data has impressed on measurements likely to be primary endpoints in the future registrational trial,' Bell Potter says.
The trial would be the first ever pivotal study for RP11, which has no current treatment and affects 1500 to 3500 Americans.
Bell Potter values PYC shares at $2.30, a 58% increment on their current value.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
13 minutes ago
- ABC News
Awash with cash. How the investment world is feeding upon itself
The tremors rumbled across Wall Street again last week, sparking concerns that the much-anticipated correction could be afoot. This time it was poor jobs numbers, adding to concerns the economy was cooling, and coming on top of a tumultuous fortnight of furious tariff negotiations with key trading partners including the European Union and Japan. Fears of the tariff impact have been building for months. Debt markets have remained on edge that the sharp increase in American tariffs would hit global growth, and fretted as to whether they would provide a one-off boost to inflation or have a more lasting effect. Stock markets, by contrast, have blithely shrugged aside all concerns and headed for the Moon. Since the meltdown in April immediately after US President Donald Trump unveiled his "liberation day" tariffs — when stocks plunged headlong into correction territory — they've regained all the lost ground and bounced back to new records. By the end of the first week in April, the Dow Jones Industrial Average had shed an incredible 19 per cent from its February peak. At any other point in history, the speed of that recovery would have seemed inconceivable. But you only need to hark back to 2020 in the early days of the pandemic when stock investors took fright and headed for the exits en masse. The crash, as harsh as it was, turned positive in record time. Within weeks, it had bounced off its lows and began an extended recovery. There was no vaccine, almost the entire global economy was in shutdown mode, and normal life was in suspension. Why? Unlike previous periods of instability, there is one distinguishing feature of the global economy right now. The world is awash with money. Cash is desperately seeking a home. And that is keeping asset prices buoyant on everything from stocks to real estate and bonds. How long can it last? Until something breaks. The end of the financial year usually brings about some kind of reckoning. It's the time when corporations open the books, declare their earnings, and deliver some guidance on how they see the future. Right now, there is an almost universal belief that stock markets are overcooked, that they've been soaring so high for so long, they are dangerously close to the Sun. Australian stocks are trading at about 20 times the value of their projected earnings. That's not quite a record. The value was higher in the aftermath of the pandemic. But it is well above the long-term average of 15 times earnings. Wall Street, on the other hand, is trading at more than 26 times forward earnings. And most of that extreme valuation is captured by just a handful of companies, the seven technology giants that are betting big on artificial intelligence (AI). Nvidia, the chip maker that has assumed the mantle of the world's most valuable corporation, is trading at more than 56 times its projected earnings. These lofty valuations, and the relatively tiny pool of corporations driving global stock markets, has many seasoned veterans fretting about the potential for a violent drop. Their fears are well-founded. Global stocks are extremely vulnerable to external shocks, and the world has no shortage of unpredictable leaders right now. But the graph below — the extraordinary almost exponential growth in US money supply — highlights a conundrum for big investors. Even In the event of some unforeseen event, what should they do with all the cash? US money supply The above graph is replicated across the developed world, in Japan, Europe, China and elsewhere. It began when money markets were deregulated in the 80s, sparking a surge in borrowings by corporations, households and government. It gathered pace in the new millennium when central banks realised they could override recessions with endless amounts of stimulus via low and, in some cases, negative interest rates. And now America is embarking upon a government-inspired, debt-fuelled spending spree that will inject even more cash into the system to chase a limited number of investment opportunities. We're playing our own part in this dangerous game. Our superannuation giants are so big, they have begun to outgrow the local market. With close to $2.9 trillion in funds — and cash flooding in each week — it's becoming increasingly difficult to find an investment target to which they're not already overexposed. The biggest funds such as Australian Super, Aware Super and the Australian Retirement Trust, have reached the limit on how much they can invest here, and now, increasingly, are looking offshore. Right now, there's only one real investment theme that's attracting global funds and that's AI. The AI race has driven Wall Street to incredible heights but has sucked vast amounts of global funds into its orbit, and by extension, into the orbit of the handful of companies spearheading the AI revolution. The so called Magnificent Seven tech companies have so dominated Wall Street's performance, they've left the other 493 companies in the S&P500 in the dust with only average returns. Australian investors, courtesy of the country's super funds, have been heavily invested in this for years, and hugely exposed should anything go wrong. While some critics hark back to the 2000 tech crash as the internet boom turned into a bust, there are significant differences. Rather than loss making operations selling dreams about future earnings, this boom has been generated by hugely profitable corporations. Nonetheless, it is a gamble with vast and ever increasing amounts of capital being poured in, particularly by Amazon, Alphabet, Microsoft and Meta. Close to $US400 billion ($617 billion) is being earmarked for new investment for the next year alone. DeepSeek, the Chinese upstart that emerged back in February was the investment world's jolt of reality, at least on the technology front. But like all the other shock waves of the past five years, the downturn was brief, muted by the flood of investment cash sprayed across the tech giants. There are serious concerns about America's role and reputation in the global economy, with the White House calling for the removal of the US Fed chief Jerome Powell and the brutal ousting of the chief of the Bureau of Labor Statistics when last week's jobs numbers disappointed. Others point to the real economy, for an outbreak of inflation or a serious slowdown in growth that may skittle the great stock market boom. But the biggest threat may come from a familiar, albeit left of vision, source. So far, the big tech firms have been funding their stupendous capital investment programs with shareholder funds. That now appears to be shifting and many now are looking to use debt. Private equity groups are refashioning themselves as bankers and becoming ever more skilled in the art of raising debt under the radar and with the usual oversight of regulators. The emergence of debt adds a whole new layer of risk to an already volatile situation. While the promise of AI so far has delivered, at least according to the big tech group's earning in recent weeks, there is always the threat that their spending — particularly on data centres — could end up horribly overdone. Investment busts have a habit of recurring every decade or so and, while painful, often are considered necessary. Once they infect banking and lending markets, that pain usually is magnified. And if we've learned anything from the events of 15 years ago, the architects usually are swept to safety.
ABC News
42 minutes ago
- ABC News
Donald Trump threatens to raise tariffs further on Indian goods for Russian oil purchases
President Donald Trump has threatened to hike tariffs on goods from India over its purchases of Russian oil, a key source of revenue for Moscow's war on Ukraine. New Delhi quickly pushed back, saying the move was unjustified and vowing to protect its interests. Mr Trump's heightened pressure on India comes after he signalled fresh sanctions on Moscow if it did not make progress by Friday towards a peace deal with Kyiv, more than three years since Russia's invasion. Moscow is anticipating talks this week with the US president's special envoy Steve Witkoff, who is expected to meet President Vladimir Putin. On Monday, US time, Mr Trump said in a post on his Truth Social platform that India was "buying massive amounts of Russian Oil" and selling it for "big profits." "Because of this, I will be substantially raising the Tariff paid by India to the USA." He did not provide details on what tariff level he had in mind. Even before the threat, an existing 10 per cent US tariff on Indian products is expected to rise to 25 per cent this week. "The targeting of India is unjustified and unreasonable," India Foreign Ministry spokesman Randhir Jaiswal said in a statement, after the announcement. India has become a major buyer of Russian oil, providing a much-needed export market for Moscow after it was cut off from traditional buyers in Europe because of the war. That has drastically reshaped energy ties, with India saving itself billions of dollars while bolstering Moscow's coffers. But India argued it "began importing from Russia because traditional supplies were diverted to Europe after the outbreak of the conflict." The world's most populous country is not an export powerhouse, but the United States is its largest trading partner. AFP/ABC
ABC News
3 hours ago
- ABC News
Tesla awards chief executive Elon Musk $44 billion worth of shares
The world's richest man, Elon Musk, has become even richer after Tesla awarded him $US29 billion ($44 billion) worth of shares in the company. It comes just six months after a judge struck down an even larger pay package worth $US56 billion ($86 billion) after a lawsuit brought by a Tesla stockholder. Mr Musk, who is the chief executive of the electric vehicle maker, will be awarded 96 million shares in Tesla, but analysts believe it signals the tech billionaire will remain with the company until 2030. Tesla said in a regulatory filing on Monday that Mr Musk must first pay Tesla $US23.34 ($36.06) per share of restricted stock that vests. That cost is equal to the exercise price per share of the 2018 pay package that was awarded to the company's chief executive. In a letter to shareholders, Tesla's board said that Mr Musk hasn't received "meaningful compensation" for eight years. The board argued that Mr Musk deserved the compensation because he has delivered "transformative and unprecedented growth" that has "translated into immense value generated for Tesla and all our shareholders." Tesla shares have plunged 25 per cent this year, largely due to blowback over the billionaire's affiliation with President Donald Trump. Tesla also faces intensifying competition from both the big Detroit automakers and from Chinese EV companies. In its most recent quarter, Tesla reported that quarterly profits plunged from $US1.39 billion ($2.15 billion) to $US409 million ($632 million). Revenue also fell and the company fell short of even the lowered expectations on Wall Street. Under pressure from shareholders last month, Tesla scheduled an annual shareholders meeting for November to comply with Texas state law. A group of more than 20 Tesla shareholders, which have watched Tesla shares plummet, said in a letter to the company that it needed to at least provide public notice of the annual meeting. Investors have grown increasingly worried about the trajectory of the company after Mr Musk had spent so much time in Washington this year. He became one of the most prominent officials in the Trump administration in its bid to slash the size of the US government. In December, Delaware Chancellor Kathaleen St. Jude McCormick reaffirmed her earlier ruling that Tesla must revoke Mr Musk's multi-billion-dollar pay package. She found that Mr Musk engineered the landmark pay package in sham negotiations with directors who were not independent. At the time, Judge McCormick also rejected an equally unprecedented and massive fee request by plaintiff attorneys, who argued that they were entitled to legal fees in the form of Tesla stock valued at more than $US5 billion ($7.7 billion). The judge said the attorneys were entitled to a fee award of $345 million. The rulings came in a lawsuit filed by a Tesla stockholder who challenged Musk's 2018 compensation package. Mr Musk has been one of the richest people in the world for several years. Wedbush analyst Dan Ives said he felt Mr Musk's stock award would alleviate some Tesla shareholder concerns. "We believe this grant will now keep Musk as CEO of Tesla at least until 2030 and removes an overhang on the stock," Mr Ives wrote in a client note. "Musk remains Tesla's big asset and this comp issue has been a constant concern of shareholders once the Delaware soap opera began." AP
